Rhythm Pharmaceuticals

Valuation Analysis

About the Company

Rhythm Pharmaceuticals en bref

Rhythm Pharmaceuticals (RYTM) is currently trading at 84,47 € with a market capitalization of 5,8 Md €. The 52-week range spans from 53,06 € to 106,64 €; the current price is 20.8% below the yearly high. Year-over-year revenue growth stands at +83.8%.

💰 Dividende

Rhythm Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Rhythm Pharmaceuticals (RYTM) au consensus : Achat Fort. L'objectif de cours moyen est de 121,71 €, soit un potentiel de +44.09% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 91,63 € à 138,76 €.

Rhythm Pharmaceuticals : la thèse d'investissement en détail

Rhythm Pharmaceuticals (RYTM) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 83.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 89.41%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 44.09% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.92, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 11.62% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 44.09% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (11.62%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Rhythm Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.